OMERS ADMINISTRATION Corp Takes Position in Aurinia Pharmaceuticals Inc $AUPH

OMERS ADMINISTRATION Corp acquired a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 92,700 shares of the biotechnology company’s stock, valued at approximately $1,573,000.

A number of other institutional investors have also recently added to or reduced their stakes in AUPH. Royal Bank of Canada increased its holdings in Aurinia Pharmaceuticals by 65.3% in the first quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company’s stock valued at $2,956,000 after buying an additional 145,179 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Aurinia Pharmaceuticals by 8.7% during the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company’s stock worth $4,048,000 after acquiring an additional 40,380 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Aurinia Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 3,497 shares during the period. Creative Planning grew its holdings in shares of Aurinia Pharmaceuticals by 21.0% in the 2nd quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 3,594 shares during the period. Finally, Legal & General Group Plc increased its stake in Aurinia Pharmaceuticals by 16.5% in the 2nd quarter. Legal & General Group Plc now owns 141,492 shares of the biotechnology company’s stock valued at $1,201,000 after purchasing an additional 20,027 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, CEO Kevin Tang acquired 343,620 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were acquired at an average cost of $15.28 per share, for a total transaction of $5,250,513.60. Following the completion of the transaction, the chief executive officer directly owned 12,838,101 shares of the company’s stock, valued at $196,166,183.28. The trade was a 2.75% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders acquired 814,606 shares of company stock valued at $12,455,129 over the last ninety days. Insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AUPH shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. Royal Bank Of Canada raised their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, Wall Street Zen lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $17.67.

Aurinia Pharmaceuticals Trading Down 1.3%

Shares of AUPH opened at $16.54 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97. Aurinia Pharmaceuticals Inc has a 1-year low of $10.34 and a 1-year high of $19.25. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of 7.22 and a beta of 1.42. The firm has a 50 day simple moving average of $15.98 and a 200-day simple moving average of $15.47.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.